Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Determination of Tumor Response Rate by RECIST and FDG-PET Criteria to Dacarbazine in Metastatic Soft Tissue and Bone Sarcoma

NCT00802880 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT00802880
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00802880 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Determination of Tumor Response Rate by RECIST and FDG-PET Criteria to Dacarbazine in Metastatic Soft Tissue and Bone Sarcoma
Lead sponsor
Washington University School of Medicine
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2009
Completion date
January 31, 2015
Enrollment
80 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sarcoma